Equity
€905,403 =
CTMED paid out €540,580 in dividends. That is 100% of the 2025 profit.
CTMED
Lifetime
7 annual accounts with figures on one time axispeak €807,221 (2025)
€807,221▲ 2.9%
peak €540,580 (2025)
€540,580▲ 0.8%
peak €905,403 (2021)
€905,403unchanged
€1.0m▲ 81.6%
peak 0.7 FTE (2025)
0.7 FTE
Board4 names since 2018
4 directors and 3 others
Documentsfilings and deeds
31-08-202631 days late
2025abbreviated format
Dividend €540,580Debts from €569,382 to €1.0mCash from €272,902 to €888,660
Key points
from the 2025 annual accountsTurnover
≈ €1.5m estimated
The accounts state no turnover.
Debts
€1.0m ▲ 81.6%
Debts rose by €464,845 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.
Filings
7 annual accounts 6 late
The 2019 accounts came latest: 91 days after the end of the period.
Starting capital
€18,600 100 shares
Position in the sector
€540,580
Higher net result than 90% of companies in human health. Sector median €125,403 · 2,767 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 26,973 companies had the same profile as CTMED has now. Each dot stands for 68 companies, two years later.
94.8%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,973 companies, not a prediction for CTMED. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 29-12-2018
Manager, since 29-12-2018
Director, since 29-12-2018
Manager, since 29-12-2018
- 50 sharesdeed of 03-01-2019
- 50 sharesdeed of 03-01-2019
Recent changes
Reappointments: (director) and (director)
Legal-form conversion: from private limited company (pre-2019) to private limited company · General meeting of 25-05-2023 · Gazette deed
First establishment
Rue du Caudia 137, Manage
Incorporation
Founding capital of €18,600, 100 shares · Founders: and · Appointments: (manager) and (manager) · published on 03-01-2019 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| CTMED Manage | €1.9m | €807,221 | 46.7% | 0.7 |
| BASTEX Fléron | €2.0m | €975,609 | 59.5% | 1.8 |
| CABINET MÉDICAL DR ABBATE & ASSOCIES Liège | €1.6m | €665,284 | 95.5% | 1.7 |
| PRAKTIJK DR. MUNYOKA ELYSEE Brussels | €1.8m | €638,708 | 59.5% | 2.2 |
| MED ZENGIN Braine-l'Alleud | €2.3m | €858,629 | 30.4% | 3.2 |
| Alain GEMAYEL Lasne | €2.6m | €559,009 | 0.2% | 0 |
| Docteur BENOIT Arnaud Bastogne | €0.9m | €885,650 | 80.7% | 0.8 |
These companies have the same main activity as CTMED: general medical practice (NACE 86210). They are comparable in size and age: total assets between €921,000 and €2.6m, founded between 2018 and 2019.
Official details
Source: KBO- Status
- Active since 29-12-2018Normal situation
- Activity
- General medical practiceNACE 86210
- Joint committee
- 330Health institutions and services · annual accounts 2025
- Establishment unit
- 2.283.357.6307170 Manage, since 01-01-2019
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Insights on CTMED
CTMED files the abbreviated format. That format states no turnover. The gross margin rose from €340,656 in 2019 to €807,221 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about CTMED
- What is the company number of CTMED?
- The company number of CTMED is 0716.964.216. The VAT number is the same number with BE in front: BE 0716.964.216.
- Where is CTMED based?
- The registered office is at Rue du Caudia 137, 7170 Manage.Company details
- What does CTMED do?
- According to the KBO register, the main activity is general medical practice (NACE 86210).
- What is the legal form of CTMED?
- CTMED is a private limited company (BV).
- When was CTMED founded?
- CTMED was founded on 29-12-2018.
- Is CTMED still active?
- Yes, CTMED is an active enterprise in the KBO register.
- How many employees does CTMED have?
- CTMED had an average of 0.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does CTMED fall under?
- In its 2025 annual accounts, CTMED states joint committee 330 (Health institutions and services).
- What is the turnover of CTMED?
- The turnover in financial year 2025 is ≈ €1.5m. This figure is estimated from the gross margin of €807,221 and 41 comparable companies (NACE 862). It probably lies between €1.0m and €2.5m.
- Is CTMED profitable?
- In financial year 2025, CTMED made a profit of €540,580.
- Where can I find the annual accounts of CTMED?
- CTMED filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CTMED due?
- CTMED must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.